Vanda Pharmaceuticals
VNDA
115 hedge funds and large institutions have $434M invested in Vanda Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 39 reducing their positions, and 21 closing their positions.
233% more call options, than puts
Call options by funds: $7.42M | Put options by funds: $2.23M
27% more capital invested
Capital invested by funds: $342M → $434M (+$92.2M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1% less funds holding
Funds holding: 116 → 115 (-1)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
8% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$17.8M |
| 2 |
Morgan Stanley
New York
|
+$4.66M |
| 3 |
TA
Teachers Advisors
New York
|
+$3.83M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$3.43M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.8M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$12.2M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$10.4M |
| 4 |
AC
Armistice Capital
New York
|
-$7.75M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.28M |
VNDA Hedge Fund Activity: Q2 2016 in Review
115 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2016, worth a combined $434M — up 27% from $342M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of VNDA and 20 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 36 added.
The largest buyer was Macquarie Group, adding an estimated $17.8M. The largest seller was Millennium Management, cutting an estimated $16.8M.
- 115 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2016, down from 116 in Q1 2016.
- Funds reported $434M of Vanda Pharmaceuticals stock for Q2 2016, up 27% quarter-over-quarter.
- 20 funds opened new Vanda Pharmaceuticals positions in Q2 2016 and 21 closed out, a net change of -1 holder.
- The largest Vanda Pharmaceuticals buyer in Q2 2016 was Macquarie Group, an estimated $17.8M added.
- The largest Vanda Pharmaceuticals seller in Q2 2016 was Millennium Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2016.